At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRS Carpenter Technology
Post-Mkt 07-21 18:56:24 EDT
588.99
+33.86
+6.10%
盘后590.00
+1.01+0.17%
17:40 EDT
High589.30Low557.98Vol620.38K
Open566.74D1 Closing555.13Amplitude5.64%
Mkt Cap29.34BTradable Cap28.56BTotal Shares49.82M
T/O361.76MT/O Rate1.28%Tradable Shares48.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Billionaires are Loading up on These Superior Stocks. Why it Pays to Follow Their Money.
Dow Jones  ·  07-18
Billionaires are Loading up on These Superior Stocks. Why it Pays to Follow Their Money.
JPMorgan ups Carpenter target, places on ‘Negative Catalyst Watch’
TIPRANKS  ·  07-14
JPMorgan ups Carpenter target, places on ‘Negative Catalyst Watch’
U.S. Research Roundup: Airbnb, Doordash, Zillow Group
Reuters  ·  07-14
U.S. Research Roundup: Airbnb, Doordash, Zillow Group
Billionaires are Loading up on These Superior Stocks. Why it Pays to Follow Their Money.
Dow Jones  ·  07-14
Billionaires are Loading up on These Superior Stocks. Why it Pays to Follow Their Money.
J.P. Morgan Remains a Buy on Carpenter Technology (CRS)
TIPRANKS  ·  07-13
J.P. Morgan Remains a Buy on Carpenter Technology (CRS)
Poolbeg Pharma Begins POLB 001 Trial, Targets Major CRS Market Opportunity
TIPRANKS  ·  07-13
Poolbeg Pharma Begins POLB 001 Trial, Targets Major CRS Market Opportunity
Is Carpenter Technology (CRS) Fully Valued Following Its Russell Index Removals?
Simply Wall St.  ·  07-10
Is Carpenter Technology (CRS) Fully Valued Following Its Russell Index Removals?
Carpenter Tech is Maintained at Positive by Susquehanna
Dow Jones  ·  07-10
Carpenter Tech is Maintained at Positive by Susquehanna
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
GlobeNewswire  ·  07-07
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Carpenter Technology Announces Conference Call and Webcast
GlobeNewswire  ·  07-01
Carpenter Technology Announces Conference Call and Webcast
Carpenter Tech is Maintained at Overweight by Keybanc
Dow Jones  ·  06-30
Carpenter Tech is Maintained at Overweight by Keybanc
Analysts’ Top Industrial Goods Picks: Carpenter Technology (CRS), AeroVironment (AVAV)
TIPRANKS  ·  06-30
Analysts’ Top Industrial Goods Picks: Carpenter Technology (CRS), AeroVironment (AVAV)
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development
GlobeNewswire  ·  06-25
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
GlobeNewswire  ·  06-14
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
GlobeNewswire  ·  06-14
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Movement Alert｜Carpenter Technology Rises 5.01% in Regular Trading, Trading at $548.98
Market Focus  ·  06-11
Movement Alert｜Carpenter Technology Rises 5.01% in Regular Trading, Trading at $548.98
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
GlobeNewswire  ·  06-11
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
GlobeNewswire  ·  06-11
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
GlobeNewswire  ·  06-11
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
GlobeNewswire  ·  06-10
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Introduction

Company Name.
Carpenter Technology
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.
Issue price:
--